*Tyvaso has primarily been studied when added to a phosphodiesterase-5 (PDE-5) inhibitor or endothelin receptor antagonist (ETRA)
4x Daily Dosing for PAH Is
MANAGEABLE
Effective Add-on Therapy that's
ACHIEVABLE
The Only 4x Daily Dosing That's
INHALEABLE

Tyvaso Is the Only Inhalable Prostanoid Approved for
4x Daily Dosing

Tyvaso® offers the power of prostacyclin for your patients. The lightweight and portable Tyvaso Inhalation System provides patients with a practical treatment option that can be planned around daily activities. Patients on Tyvaso start and stay on 1 ampule a day.

Learn more about Tyvaso by clicking on the links below:

  • Evaluate the benefits and risks of Tyvaso therapy for your patients with PAH
    Learn More
  • The vasodilatory and antiplatelet activities of a prostanoid
    Learn More
  • Improvement in 6MWD at peak and trough exposure when used in addition to oral monotherapy
    View Clinical Study
  • Four times daily dosing during waking hours—treatment timing can be adjusted for planned activities
    Dosage & Administration
  • Patient-friendly delivery with the lightweight, portable, handheld Tyvaso Inhalation System
    Learn More
  • The most common adverse events seen in patients taking Tyvaso
    View Important Patient Considerations

Indication

Tyvaso is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability. Studies establishing effectiveness included predominately patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%).

The effects diminish over the minimum recommended dosing interval of 4 hours; treatment timing can be adjusted for planned activities.

While there are long-term data on use of treprostinil by other routes of administration, nearly all controlled clinical experience with inhaled treprostinil has been on a background of bosentan (an endothelin receptor antagonist) or sildenafil (a phosphodiesterase type 5 inhibitor). The controlled clinical experience was limited to 12 weeks in duration.

Important Safety Information for Tyvaso

  • Tyvaso is intended for oral inhalation only. Tyvaso is approved for use only with the Tyvaso Inhalation System
  • The safety and efficacy of Tyvaso have not been established in patients with significant underlying lung disease (such as asthma or chronic obstructive pulmonary disease) and in patients under 18 years of age. Patients with acute pulmonary infections should be carefully monitored to detect any worsening of lung disease and loss of drug effect
  • Tyvaso may increase the risk of bleeding, particularly in patients receiving anticoagulants
  • In patients with low systemic arterial pressure, Tyvaso may cause symptomatic hypotension. The concomitant use of Tyvaso with diuretics, antihypertensives, or other vasodilators may increase the risk of symptomatic hypotension
  • Hepatic or renal insufficiency may increase exposure to Tyvaso and decrease tolerability. Tyvaso dosage adjustments may be necessary if inhibitors of CYP2C8 such as gemfibrozil or inducers such as rifampin are added or withdrawn
  • The most common adverse events seen with Tyvaso in ≥4% of PAH patients and more than 3% greater than placebo in the placebo-controlled clinical study were cough (54% vs 29%), headache (41% vs 23%), throat irritation/pharyngolaryngeal pain (25% vs 14%), nausea (19% vs 11%), flushing (15% vs <1%), and syncope (6% vs <1%)
  • Tyvaso should be used in pregnancy only if clearly needed. Caution should be exercised when Tyvaso is administered to nursing women

For more information about Tyvaso, please see the Full Prescribing Information, Patient Package Insert, and the Tyvaso Inhalation System Instructions for Use Manual. Questions? Call the Customer Service Line at 1-877-UNITHER (1-877-864-8437).

You Are Now Leaving Tyvaso.com

Click "CONTINUE" to proceed or "RETURN" to return to TYVASO.com

Close Window Continue Return

You Are Now Leaving Tyvaso.com

The content of the linked site is the sole responsibility of the site provider. United Therapeutics Corporation does not control or endorse this third-party site.

Click "CONTINUE" to proceed or "RETURN" to return to TYVASO.com

Close Window Continue Return